The largest database of trusted experimental protocols

6 protocols using crl 2947

1

Culturing Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
The CT26.WT colon cancer cells (CRL-2638™), EMT6 breast cancer cells (CRL-2755™), RENCA renal cancer cells (CRL-2947™), and 4T1 breast cancer cells (CRL-2539™) were obtained from ATCC. The CT26 and 4T1 cells were cultured in RPMI-1640 (ATCC® 30-2001™), supplemented with 10% v/v fetal bovine serum ((#100-106, GeminiBio), penicillin-streptomycin (100 U/mL-100 μg/mL, #15140163, Gibico™), and 2 mM L-alanyl-L-glutamine (#25-015-CI, Glutagro™ Corning®). EMT6 cells were cultured in 85% v/v Waymouth's MB 752/1 medium with 2 mM glutamine (#11220035, Gibico™) and 15% v/v FBS, supplemented with penicillin-streptomycin. RENCA cells were cultured in RPMI-1640, 10% v/v FBS, penicillin-streptomycin, supplemented with 2 mM L-ananyl-Lglutamine, 0.1 mM non-essential amino acids (#M7145-100ML, Sigma), and 1 mM sodium pyruvate (#11360070, Gibico™). All formulated cell culture media were sterilized by filtration (#569-0020, ThermoFisher) before use. Cells were cultured in cell culture flasks (430641U, Corning®) or dishes (#12-556-003, Thermo Scientific™) at 37 °C in a moisturized incubator with 5% CO2.
+ Open protocol
+ Expand
2

Murine and Human RCC Cell Line Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols
Murine RCC cell line Renca (ATCC® CRL-2947™) and human RCC cell line 769-P (ATCC® CRL-1933™) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, non-essential amino acids (NEAA) (0.1 mM extra only for Renca), 100 U/mL penicillin, and 100 μg/mL streptomycin. Caki-1 cell line (ATCC® HTB-46™) was cultured in McCoy’s 5a medium modified by adding 10% fetal bovine serum. All cells were maintained in an incubator with 95% humidified atmosphere and 5% CO2 at 37°C. Subculture was performed when the cells were 80–100% confluent. All the cells were purchased from ATCC (VA, USA). Different treatment groups contained: saline, cyclophosphamide (Cytoxan, 200 μM), 5-fluorouracil (5-FU, 15 μM), and paclitaxel (8 nM). Each drug was added to incubate for 24 h.
+ Open protocol
+ Expand
3

Cell Culture Conditions for Cancer and Kidney Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
The human T24 urinary bladder carcinoma cell line (HTB-4; ATCC, Manassas, VA, USA) and the human HEK293 epithelial kidney cell line (CRL-1573; ATCC, Manassas, VA, USA) were cultured in DMEM GlutaMAX. The murine RenCa renal cortical adenocarcinoma cell line from a male BALB/c mouse (CRL-2947, ATCC, Manassas, VA, USA) and the human A549 lung carcinoma cell line (CCL-185, ATCC, Manassas, VA, USA) were cultured in RPMI 1640 GlutaMAX and Ham’s F12 Nutrient Mix GlutaMAX media (31765035, Thermo Scientific™, Waltham, MA, USA), respectively. All media were supplemented with 10% FBS, 100 units/mL of penicillin–streptomycin (pen/strep) (15140122; Thermo Scientific™, Waltham, MA, USA), and 1 mM sodium pyruvate (11360070; Thermo Scientific™, Waltham, MA, USA). All cells were maintained at 37 °C and 5% CO2.
+ Open protocol
+ Expand
4

Therapeutic Efficacy of ASO 1560S in RENCA Xenograft

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 4

100,000 RENCA cells (ATCC® CRL2947™ Mus musculus kidney renal adenocarcina) were injected subcutaneously at day 0. At day 12, tumors of an average size of 800 mm3 were removed and the site of the tumor was washed with 100 μg of Control Oligo ASO 154 (4 animals) or ASO 1560S (5 animals) in 200 μl, both formulated in liposomes. The animals were sutured and intravenously injected at the site of the removed tumor with 100 μg of ASO 154 (FIG. 11, squares) or ASO 1560S (FIG. 11, triangles), both formulated in liposomes, in 250 μl. No further treatment was given. At day 40, (30 days post-surgery), all the control animals had died with tumors of an average size of 1,200 mm3 and extensive metastasis, while all animals treated with ASO 1560S had no tumors and were still alive at day 61 (FIG. 11).

+ Open protocol
+ Expand
5

Murine Melanoma and Renal Carcinoma Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols
The tests were carried out with murine melanoma B16-F10 (given by Prof. J. Dulak, Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Cracow, Poland; authenticated in 2021, ATCC) and renal carcinoma RenCa (CRL-2947™, ATCC, Manassas, VA, USA) cell lines. Cells were maintained in standard culture conditions: humidified atmosphere containing 5% CO2 at 37 °C, using RPMI medium—RPMI-1640 GlutaMaxTM (ThermoFisher Scientific, Waltham, MA, USA), with 10% FBS (v/v) (ThermoFisher Scientific). Cells were passaged using Accutase solution (Biolegend, San Diego, CA, USA) after confluence reached 70–80%. Cells used were Mycoplasma free as assayed with PCR Mycoplasma Test (Biomedica, Piaseczno, Mazowieckie, Poland) and did not exceed 15th passage.
+ Open protocol
+ Expand
6

Generation of Chimeric Organoids with Kidney Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mouse Renca cells (ATCC® CRL-2947™) and HeLa cells were obtained from the American Type of Culture Collection (ATCC) and had been verified via short tandem-repeat profiling. The mK4 cell line has been described previously (Valerius et al., 2002 (link)). The cells were passaged in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin in 5% CO2 at 37°C. YFP-Renca, -HeLa and -mK4 cells were generated by transfection with the pcDNA3.1+ YFP cDNA construct. Cells in which the construct had integrated into the genome were enriched via puromycin-mediated selection and FACS (BD FACSAria™ IIIu). The YFP-expressing cells were used to make the chimeric organoids with embryonic kidney nephron progenitor cells. A panel of siRNAs (Sigma-Aldrich) was used to knock down their respective target mRNAs. The MISSION siRNA (Sigma-Aldrich) was used as a control.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!